最終更新日：2022/12/24
The overexpression of miR-630 in breast cancer cells that are resistant to HER-targeted drugs significantly restores the efficacy of those drugs (e.g., lapatinib, neratinib and afatinib), which indicates that miR-630 can be used as a diagnostic and predictive marker to gauge the treatment response to HER-targeted drugs.
編集履歴（0）
元となった例文
The
overexpression
of
miR-630
in
breast
cancer
cells
that
are
resistant
to
HER-targeted
drugs
significantly
restores
the
efficacy
of
those
drugs
(e.g.,
lapatinib,
neratinib
and
afatinib),
which
indicates
that
miR-630
can
be
used
as
a
diagnostic
and
predictive
marker
to
gauge
the
treatment
response
to
HER-targeted
drugs.
